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Peroxisome-Proliferator-Activated Receptor 
Activates Fat Metabolism to Prevent Obesity
chemical potential gradient) for subsequent heat con-
version. Adaptive thermogenesis is a physiological de-
fense against obesity (Lowell and Spiegelman, 2000;
Yong-Xu Wang,1 Chih-Hao Lee,1,2 Sambath Tiep,1
Ruth T. Yu,1 Jungyeob Ham,3 Heonjoong Kang,3
and Ronald M. Evans1,2,*
Spiegelman and Flier, 2001); however, at the transcrip-1Gene Expression Laboratory
tional level, how this process is controlled, in particular2 Howard Hughes Medical Institute
how fuel oxidation and energy uncoupling is integrated,The Salk Institute
is not well understood.10010 North Torrey Pines Road
Peroxisome proliferator-activated receptors (PPARs)La Jolla, California 92037
are ligand-activated transcription factors belonging to3 Marine Biotechnology Laboratory
the nuclear receptor superfamily (Kersten et al., 2000;Oceanography Program
Chawla et al., 2001b). They form obligate heterodimersSchool of Earth and Environmental Sciences
with the retinoid X receptor and bind to defined PPARSeoul National University, NS-80
elements in the promoter region of target genes. TheSeoul 151-747
PPAR subgroup comprises three closely related mem-Korea
bers: PPAR, , and . They are activated by a variety
of fatty acids, fatty acid derivatives, and synthetic com-
pounds. Each member displays a tissue-selective ex-Summary
pression pattern, with PPARand PPARpredominantly
in the liver and adipose tissue, respectively, and PPARIn contrast to the well-established roles of PPAR and
in many tissues. Genetic and pharmacological studiesPPAR in lipid metabolism, little is known for PPAR
have revealed distinct roles of PPAR and PPAR in lipidin this process. We show here that targeted activation
metabolism. PPAR serves as an essential regulator forof PPAR in adipose tissue specifically induces ex-
adipocyte differentiation and promotes lipid storage inpression of genes required for fatty acid oxidation and
mature adipocytes by increasing the expression of sev-energy dissipation, which in turn leads to improved
eral key genes in this pathway (Rosen and Spiegelman,lipid profiles and reduced adiposity. Importantly, these
2001; Berger and Moller, 2002). These two importantanimals are completely resistant to both high-fat diet-
functions of PPAR in adipocytes are suggested toinduced and genetically predisposed (Leprdb/db) obe-
largely account for the insulin sensitizing effects of thesity. As predicted, acute treatment of Leprdb/db mice
anti-diabetic thiazolidinediones (Yamauchi et al., 2001b).with a PPAR agonist depletes lipid accumulation. In
In contrast, PPAR enhances fatty acid combustion inparallel, PPAR-deficient mice challenged with high-
liver by upregulating genes encoding enzymes in -oxi-fat diet show reduced energy uncoupling and are
dation and hence mediates the hypolipidemic effects ofprone to obesity. In vitro, activation of PPAR in adipo-
the fibrates (Reddy and Hashimoto, 2001; Berger andcytes and skeletal muscle cells promotes fatty acid
Moller, 2002). While this PPAR-regulated -oxidationoxidation and utilization. Our findings suggest that
pathway in the liver plays a major role in generatingPPAR serves as a widespread regulator of fat burning
ketone bodies to support general fuel needs during fast-and identify PPAR as a potential target in treatment
ing, similar mechanisms must exist within the peripheralof obesity and its associated disorders.
tissues to enable local response to energy load and
demands.Introduction
The functions of PPAR remain largely mysterious.
Besides the demonstration of its critical role in epider-
In western cultures, excess adipose mass, or obesity,
mal maturation and skin wound healing (Michalik et al.,
has reached epidemic proportions, resulting in meta- 2001; Tan et al., 2001), recent studies have also linked
bolic syndrome or syndrome X, typified by type 2 diabe- this receptor to lipid metabolism. Synthetic PPAR ago-
tes, cardiovascular disease, hypertension, and hyperlip- nists promote cholesterol accumulation in human mac-
idemia. In mammals, white fat and brown fat serve as rophages (Vosper et al., 2001) and increase serum HDL
major sites to control fatty acid metabolism and energy while lowering triglyceride levels in obese animal models
homeostasis (Lowell and Spiegelman, 2000; Spiegelman (Leibowitz et al., 2000; Oliver et al., 2001). Interestingly,
and Flier, 2001). White adipose stores energy in the form although the large percent of PPAR null mutant mice
of triglycerides, which is released as free fatty acids in are embryonically lethal due to placental defects, the
times of energy need, while brown adipose dissipates small number of mice that do survive show decreased
energy as heat by uncoupling ATP production from bio- adiposity (Peters et al., 2000; Barak et al., 2002). How-
chemical respiration. This energy dissipation process, ever, no reduction of fat mass is observed in adipose-
termed adaptive thermogenesis, also occurs in skeletal specific ablation of PPAR mice (Barak et al., 2002),
muscle. While a set of uncoupling proteins (UCPs) on the indicating a complex, nonautonomous action. These
mitochondrial inner membrane are the ultimate effectors data collectively implicate PPAR in lipid homeostasis;
for adaptive thermogenesis, they must coordinate with but which metabolic pathway it regulates in vivo and
fuel oxidation, which generates the energy (electro- whether it functionally overlaps with PPAR or PPAR
remain unclear.
In an attempt to pinpoint the in vivo functions of*Correspondence: evans@salk.edu
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PPAR, we undertook a gain-of-function approach by
selectively expressing an active form of PPAR in adi-
pose tissue. The resulting transgenic mice display de-
creased lipid accumulation in both adipose tissue and
serum. The mice are lean and are protected from obe-
sity. Additionally, short-term treatment of obese mice
with PPAR agonist causes a dramatic lipid depletion
in tissues. These phenotypes are consistent with an
elevated energy expenditure. Indeed, we find that
PPAR activates an array of genes required for fatty
acid combustion and uncoupling, but not that of genes
involved in lipogenesis and storage, which are controlled
by PPAR. Furthermore, PPAR-deficient mice fed with
high-fat diet display reduced energy uncoupling and are
prone to obesity. In corroboration with these in vivo
findings, we demonstrate that activation of PPAR stim-
ulates -oxidation and triglyceride utilization in adipo-
cytes and myocytes. Our data suggest that PPAR is
a key regulator of fat burning in peripheral tissues by
coordinating fatty acid oxidation and energy uncoupling.
Results
Activation of PPAR in Adipose Tissue Decreases
Fat Mass and Lipid Accumulation
We fused the 78 amino acid VP16 activation domain of
the herpes simplex virus to the N-terminal end of PPAR.
In cell transfection assays, this fusion protein (VP16-
PPAR) shows potent ligand-independent transactiva-
tion on our synthetic pan-PPAR response element, but
not on the response elements of other nuclear receptors
(data not shown). Like wild-type PPAR, VP16-PPAR
has no effect on a reporter containing a native PPAR-
specific response element we identified recently (Y.
Barak and R.M.E., unpublished data), suggesting that
VP16-PPAR has no altered promoter selectivity. We
expressed VP16-PPAR in adipose tissue under the
control of the enhancer-promoter region of the adipo-
cyte fatty acid binding protein (aP2) gene (Ross et al.,
1990). Three transgenic founders a, b, and c were ob-
tained, which are distinguishable from their littermates
due to a marked reduction in body weight and adiposity
Figure 1. Reduced Adiposity in VP16-PPAR Transgenic Mice with-(Figure 1). Founder a represents the most severe case
out Lipid Accumulation in Other Tissuesand lacks any visible white fat. This fatless phenotype
(A) (Top image) A ventral view of founder a and its control littermate.resembles that of lipoatrophic mice caused by defects
Note the complete loss of reproductive fat in the transgenic mouse.in adipogenesis (Moitra et al., 1998; Shimomura et al.,
(Lower image) H&E stained sections of liver from founder a and its
1998; Barak et al., 1999). However, none of these lines control littermate.
including founder a exhibit other features of lipoatrophic (B) (Top image) A ventral view of founder b and its control littermate.
(Lower image) A comparison of reproductive fat pads. Founder cmice, such as hypertriglyceridemia, enlarged viscera,
exhibits essentially the same reduced fat phenotype as founder b.or fatty liver (Figure 1A and data not shown). These
distinctions argue against an adipogenesis defect and
raise the possibility that the fat pad in our transgenic
mice may have increased fatty acid consumption, anti-PPAR and anti-VP16 antibodies (Figures 2B and
2C). Compared to that of endogenous PPAR, the levelthereby precluding significant storage in either liver or
other organs. Founder b and c show similar reduction of VP16-PPAR protein is lower in white fat (WAT), but
is similar or slightly higher in brown fat (BAT). Adipocyte-in fat pad size (Figure 1B and see Figure 3D), and based
on reproductive competency (normal size litters and ex- differentiation-related protein (ADRP) is a lipid droplet
coating protein and its expression is induced by PPARpected ratio of transgene), a cohort was expanded from
the c male. activation (Vosper et al., 2001). Indeed, Northern blot
analysis revealed a 3-fold increase of ADRP gene ex-We estimated that there are 2–3 copies of the trans-
gene present in the genome (Figure 2A). The transgene pression in the brown fat of transgenic mice, confirming
that the VP16-PPAR is functional in vivo (Figure 2D).is expressed in both white fat and brown fat but is absent
in other tissues, as shown by Western blot analysis with Interestingly, we did not observe a significant induction
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Figure 2. Expression and Functional Verification of the VP16-PPAR Transgene
(A) Southern blot analysis. Genomic tail DNA (20 g/lane) from wild-type (WT) and transgenic (TG) mice was digested with HindIII/EcoRV,
separated on agarose gel, and probed with PPAR cDNA.
(B) Protein extracts from brown fat (BAT), reproductive fat (RDWAT), and inguinal fat (IWAT) were assayed for PPAR and VP16-PPAR by
Western blot analysis with PPAR antibodies. Lane 1 (virus) was loaded with protein extracts generated from 3T3-L1 cells infected with PPAR
and VP16-PPAR adenovirus to show the position of the two proteins. Note, for reasons unclear, PPAR and VP16-PPAR from adipose
tissue migrate slower than from 3T3-L1 cells and higher amount of PPAR is retained on the top portion of the gel than that of VP16-PPAR
(not shown), thus the protein levels of PPAR and VP16-PPAR in brown fat are approximately equal.
(C) Protein extracts from BAT, RDWAT, IWAT, liver, and muscle were assayed for VP16-PPAR by Western blot analysis with VP16 antibodies.
Each lane was loaded with equivalent weight of tissues.
(D) Total RNA (10 g/lane) from brown fat of 3 control littermates (WT) and 4 transgenic mice (TG) was analyzed by Northern blot with probes
for ADRP and  actin.
of ADRP in white fat, indicating that target gene regula- mine whether the reduced fat weight and lipid accumula-
tion occur at the expense of lipid buildup in the circula-tion by PPAR is highly tissue or cell-type-selective.
On a standard diet, despite a daily food intake similar tion, we assayed serum lipid levels. While levels of total
cholesterol remain unchanged, those of total triglycerideto that of control littermates when measured in individu-
ally housed mice (Figure 3A), the transgenic mice are and free fatty acid are significantly decreased (Figure
3F). These results, together with the lack of lipid accu-about 20% smaller in body weight at 4 months old, and
this difference is increased to 35% at 12 months old mulation in liver and muscle, are consistent with our
hypothesis that activation of PPAR in adipose pro-(Figure 3B). In contrast, transgenic expression of the
VP16 activation domain alone in adipose tissue (aP2- motes fatty acid consumption.
VP16) produces no discernable differences relative to
control nontransgenic littermates in body weight, physi- Activation of PPAR in Adipose Protects against
Obesity and Hyperlipidemiaology, or histology (Figure 3C and data not shown). We
measured the weight of various tissues normalized by In principle, enhanced fatty acid utilization should pro-
tect mice against high-fat diet induced obesity. Accord-body weight in VP16-PPAR transgenic mice. There is
a 40% decrease in the reproductive white fat depot ingly, we challenged 8-week-old mice with a high-fat
diet containing 35% (w/w) fat for 32 days to stimulate(Figure 3D). This is in marked contrast to other tissues
including brown fat, liver, heart, and kidney, which have weight gain. As shown in Figure 4A, weight gain is highly
blunted in the transgenic mice relative to the controlweights similar to wild-type and exhibit no gross abnor-
malities. Adipose tissues, but not other tissues, show littermates. A statistical difference is observed as early
as the first two weeks of feeding. By the end of thisstriking morphological changes (Figure 3E). In control
littermates, white fat adipocytes are uniform in size, feeding period, the control littermates have become
mildly obese (38.60  0.85 g, and Figure 4B), while thewhereas in transgenic mice, adipocytes, especially for
inguinal and retroperitoneal fat depots, are smaller and transgenic mice still weigh slightly less than chow diet-
fed nontransgenic mice (24.46  0.64 versus 26.84 heterogeneous in size, indicating that the reduction in
total fat mass may result from less triglyceride accumu- 0.37 g). The net weight gains are 5.27  0.61 g and
12.40  0.76 g, respectively, for transgenic and controllation rather than a reduced number of adipocytes. Re-
duction of lipid accumulation is even more prominent littermates fed with the high-fat diet. The body weight
difference is largely due to the difference in fat mass.in brown fat. Brown fat adipocytes normally contain
multiple lipid droplets. Both the number and the size of The inguinal, reproductive, and retroperitoneal fat de-
pots each weigh one-third of that of control littermates,lipid droplets are reduced in transgenic mice. To deter-
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Figure 3. Phenotypes of the Transgenic Mice
(A) Food intake measured over 15 days in individually housed four-month-old male mice (n  7–11). Food intake was averaged for each mouse
and then averaged for each group.
(B) Body weights of four-month-old mice (n  6 for male; n  5–6 for female), and of twelve-month-old mice (n  9–14 for male; n  6–8 for
female).
(C) Body weights of eleven-month-old male aP2-VP16 transgenic mice and their nontransgenic littermates (n  8). No body weight difference
was observed in female mice either. The expression of VP16 transgene in adipose was shown by northern analysis.
(D) Weights of white fat depots normalized by body weight at seven and five months of age, respectively, for male (n  5–6) and female (n 
5–6) mice.
(E) Histology of adipose tissue of the transgenic mice. Sections from inguinal fat (IWAT), retroperitoneal fat (RETROWAT), reproductive fat
(RDWAT), brown fat (BAT), and liver were stained with H&E.
(F) Steady-state serum levels of triglycerides (n  4–6), free fatty acids (n  5–6), and total cholesterol (n  4–6). Five-month-old female mice.
Empty bar, wild-type; filled bar, transgenic.
and only one-half when normalized by body weight (Fig- As expected, high-fat feeding causes adipocyte hyper-
trophy and massive lipid accumulation in both white fature 4C). While high-fat feeding increases serum triglyc-
eride and free fatty acid levels by 2-fold in control lit- and brown fat in control littermates, while little, if any,
of these changes are found in transgenic mice (Figuretermates, activation of PPAR in adipose results in a
lipid profile close to that of wild-type mice under the 4E, and data not shown). Moreover, nontransgenic mice
develop fatty liver, suggesting a saturated lipid storagestandard chow diet (Figure 4D, compare to Figure 3F).
PPAR in Lipid Metabolism and Obesity Resistance
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Figure 4. Activation of PPAR in Adipose Tissue Protects from Obesity and Hyperlipidemia
(A) Eight-week-old male mice (n  6–7) were fed with a high-fat diet. The increases in body weights were calculated based on the initial body
weight at day 0 of high-fat feeding. The initial body weights are 19.20  0.46 g for transgenic mice, and 26.20  0.24 g for control littermates.
(B) Photographs of representative control littermate and transgenic mice after five weeks of high-fat diet feeding.
(C) Weights of white fat depots normalized by body weight (n  7–9).
(D) Steady-state serum levels of triglycerides (n  4) and free fatty acids (n  4). Serum levels of total cholesterol were not assayed.
(E) Prevention of lipid accumulation in adipose tissue and liver. Sections of brown fat and liver were stained with H&E.
(F) Photographs of representative Leprdb/db (Left) and Leprdb/db/VP16-PPAR (Right) mice.
in adipose. However, no appreciable fatty acid accumu- continue to increase with age. At 16 weeks, Leprdb/db
mice are overtly obese and weigh 54.46  1.26 g (n lation in liver is observed in transgenic mice (Figure
4E). Thus activation of PPAR in adipose, possibly via 6), while Leprdb/db/VP16-PPAR mice only weigh 31.70 
1.35 g (n  5) (Figure 4F), which is close to that of theirincreasing energy expenditure, counteracts high-fat-
induced obesity, and prevents fatty liver and hyperlip- control littermates (33.86  1.80 g, n  5). These results
demonstrate that activation of PPAR in adipose re-idemia.
We next examined whether activation of PPAR in verses the obesity phenotype of Leprdb/db mice and also
suggest that the anti-obesity function of PPAR doesadipose tissue can protect a genetically fat model,
Leprdb/db mice, from developing obesity. Leprdb/db mice not require the presence of leptin signaling pathway.
exhibit markedly increased adiposity due to hyperpha-
gia caused by mutation in the leptin receptor gene (Chen PPAR Agonist Depletes Tissue Lipid Storage
in Leprdb/db Miceet al., 1996; Lee et al., 1996). We obtained Leprdb/db mice
harboring the transgene. At 5 weeks, the body weight We extended our in vivo studies of Leprdb/db mice using
a PPAR specific agonist, GW501516 (Oliver et al., 2001).differences between Leprdb/db and Leprdb/db/VP16-PPAR
mice are distinguishable. The body weight differences Age- and weight-matched Leprdb/db mice were treated
Cell
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Figure 5. PPAR Agonist Rapidly Depletes
Lipid Accumulation of Brown Fat and Liver in
Leprdb/db Mice
Age- and weight-matched Leprdb/db mice were
treated with vehicle or GW501516 for 7 days.
Sections of brown fat, liver, and inguinal fat
were then stained with H&E.
with vehicle or GW501516 for 7 days. We then examined UCPs. All three UCPs are expressed in brown fat with
UCP1 being most abundant. Activation of PPAR in-the histology of brown fat and liver, since these two
tissues accumulate unusual amounts of lipids in Leprdb/db duces expression of UCP1 and UCP3 in brown fat by
3.0- and 2.8-fold, respectively, but has no effect on themice. As shown in Figure 5, brown fat in vehicle-treated
Leprdb/db mice resembles white fat, each cell filled with expression of UCP2. We next examined the expression
of genes encoding enzymes for fatty acid -oxidation.a single massive lipid droplet, pushing the nucleus to
the cell periphery. Remarkably, in GW501516 treated Long chain acyl-CoA synthetase (LCAS; 2.2-fold), very
long chain acyl-CoA synthetase (VLCAS; 2.1-fold), acyl-Leprdb/db mice, brown fat adipocytes show increased mi-
tochondria-rich eosinophilic staining, disappearance of CoA oxidase (AOX; 2.0-fold), the muscle form of carni-
tine palmitoyltransferase-1 (mCPT1; 1.7-fold), long chainlarge lipid droplets, and replacement with multiple small
droplets. Thus, even a relatively short-term agonist acyl-CoA dehydrogenase (LCAD; 1.7-fold), and very
long chain acyl-CoA dehydrogenase (VLCAD; 1.9-fold)treatment leads to a rapid restoration of brown fat ap-
pearance with reduced lipid content and enhanced met- are all upregulated in brown fat. Interestingly, these oxi-
dation genes have previously been found to be inducedabolic activity. As might be predicted, a vast reduction
of lipid accumulation in the liver was also found (Figure by PPAR agonists in the liver (Reddy and Hashimoto,
2001; Berger and Moller, 2002). We also observed a mild5). We did not see significant histological changes of
white fat, presumably due to the very short period of but significant induction of hormone-sensitive lipase
(HSL; 1.7-fold), which catalyzes triglyceride hydrolysistreatment. These observations essentially mirror the
phenotypes in the transgenic mice fed with high-fat diet, in adipocytes. Surprisingly, activation of PPAR causes
no significant changes for genes involved in lipogenesisreaffirming the role of PPAR activation in fatty acid
metabolism. (SREBP1) and lipid storage (CD36 and aP2), which are
induced by PPAR agonists in adipose tissue (Yamauchi
et al., 2001b; Berger and Moller, 2002). Expression ofPPAR Selectively Activates Genes of Fatty Acid
Oxidation and Energy Uncoupling adipocyte-secreted proteins, ACRP30 and resistin,
which are also regulated by PPAR and are implicatedThe data presented above indicate an upregulation of
fatty acid combustion by activation of PPAR. We in fatty acid and glucose metabolism (Berg et al., 2001;
Steppan et al., 2001; Yamauchi et al., 2001a), remainssought to understand the molecular basis underlying
this metabolic change. We compared the expression of unchanged. In white fat, we observed no difference for
most of these genes, except for UCP1, which shows agenes involved in fatty acid metabolism by Northern
blot and phosphorimager analysis (Figures 6A and 6B). robust induction (Figure 6B). UCP1 is the hallmark for
brown fat. The ability of PPAR to promote a brown fat-Brown fat is the major tissue for adaptive thermogenesis
that dissipates energy as heat via uncoupling protein like feature of white fat is reminiscent of that of the
PPAR in Lipid Metabolism and Obesity Resistance
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Figure 6. PPAR Activates Genes Required for Oxidation and Thermogenesis in Adipose Tissue
(A–C) Northern blot analysis of gene expression in brown fat (A), white fat (B), and liver (C) of the transgenic mice. Total RNA (10 g/lane)
was hybridized with indicated probes. Intensity of the signals was quantitated by phophorimager analysis and the fold induction in the
transgene was calculated after normalization with  actin signal. Full names of the probes used are found in the text.
(D) PPAR null is prone to high-fat-induced obesity. Eight-month-old male PPAR null mice were fed with chow diet or high-fat diet for 3
weeks.
(E) Male-floxed PPAR mice with or without aP2-CRE were fed with high-fat diet for 1 week. RNA was isolated from brown fat and hybridized
with UCP1 probe.
(F) RNA from brown fat of mice used in (D) was isolated and analyzed for UCP1 expression.
transcriptional coactivator PGC-1 (Puigserver et al., gregate, our gene expression data reveal that PPAR
activates each of the three steps of fatty acid catabolism1998); however, no upregulation of PGC-1 is found in
either white fat or brown fat of the transgenic mice (data in brown fat: hydrolysis, oxidation, and uncoupling of
oxidative phosphorylation. The ability of PPAR activa-not shown). Although the level of UCP1 induced by
PPAR in white fat is low relative to that in brown fat, tion to prevent high-fat-induced fatty liver raised the
possibility that this might be due to an indirect effectits functional significance cannot be excluded, given
the large quantity of white fat. Indeed, low levels of on fatty acid synthesis in liver. An examination of the
expression levels of acetyl-CoA carboxylase 1(ACC1),transgenic UCP1 expression in white fat are sufficient
to protect against obesity (Kopecky et al., 1996). In ag- fatty acid synthase (FAS), and SREBP1 in the liver re-
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veals no obvious differences of transgenic mice and In agreement with increased glycerol release, the
amount of total triglyceride in cells decreases signifi-control littermates (Figure 6C). These results suggest
cantly (Figure 7B). Moreover, we observed no differencethat the observed phenotypes are indeed direct conse-
in the levels of free fatty acids in the media betweenquences of activated metabolism in adipose tissue.
control and PPAR or VP16-PPAR overexpression ex-Having established that PPAR acts as a thermogenic
periments (data not shown), suggesting that the freetranscriptional factor, we reasoned that ablation of
fatty acids derived from triglyceride hydrolysis are effec-PPAR should constrain the oxidative response, re-
tively burned.sulting in increased body weight gain upon energy over-
To determine whether endogenous PPAR promotesload. As previously reported, PPAR null mice are runted
fatty acid utilization and to provide direct evidence thatat birth and during the first 12 months and weigh much
PPAR acts upon the -oxidation pathway, we mea-less than wild-type mice under normal chow diet. How-
sured the level of -oxidation in 3T3-L1 preadipocytes.ever, when placed on a high-fat diet, they gain weight
Remarkably, while agonists for PPAR (WY14643) orrapidly and their body weights surpass those of wild-
PPAR (BRL49653) have little effect, PPAR agonisttype mice after a 3 weeks trial (41.8  1.97 g versus
GW501516 stimulates -oxidation by 50%, demonstra-34.9  2.34 g, n  6, P  0.05; Figure 6D). In contrast,
ting that activation of endogenous PPAR is sufficientduring this feeding period, age-matched PPAR null
to increase fatty acid combustion (Figure 7C). Basalmice under chow diet or age-matched wild-type mice
-oxidation is increased by overexpressing PPAR, andunder either chow diet or high-fat diet show little weight
addition of GW501516 or overexpression of VP16-changes. We also observed that PPAR null mice accu-
PPAR results in a 2-fold increase (Figure 7D). In con-mulate much higher amount of lipids in brown fat than
trast, overexpression of PPAR plus its agonist BRL49653controls under high-fat diet (data not shown). We then
has only a marginal effect on -oxidation, consistentexamined UCP1 expression in brown fat of both adi-
with distinct functions for individual PPAR isoforms.pose-specific PPAR knockout and null mice (Barak et
We next investigated whether PPAR can play a simi-al., 2002). Under normal chow diet, levels of UCP1 are
lar role in fatty acid catabolism and uncoupling in skele-similar between floxed PPARmice (controls) and floxed
tal muscle. C2C12 cells were differentiated into myo-PPAR mice with aP2-CRE (knockouts). Whereas UCP1
tubes and then treated with PPAR agonists. Consistentis robustly induced after 1 week high-fat feeding in con-
with our observations in adipocytes, the PPAR agonisttrol animals, the induction is significantly compromised
GW501516 significantly increases fatty acid oxidationin knockouts (Figure 6E). Similar decrease of UCP1 ex-
in myotubes, with no effects found for either PPAR orpression is observed in PPAR null mice fed with high-
PPAR agonists (Figure 7E). Activation of ectopicallyfat diet (Figure 6F). Thus, under conditions of high-fat
expressed PPAR in myotubes leads to a much morediet, loss of PPAR in adipose tissue or in the whole
robust stimulation (Figure 7E). Again, activation of ec-animal results in impaired thermogenesis, partially ex-
topically expressed PPAR produces little effect. Inplaining the rapid weight gain of null mice.
agreement with the oxidation data, the GW501516 com-
pound induces the expression of genes required for
PPAR Stimulates Fatty Acid Oxidation fatty acid oxidation and uncoupling, while little or no
in Cultured Adipocytes and Myocytes, induction is observed for PPAR or PPAR agonists
and Associates with the Thermogenic (Figure 7F). Conversely, GW501516 treatment has no
Cofactor PGC-1 In Vivo effects on genes for lipogenesis or fatty acid transport
We asked whether the function of PPAR could be reca- (Figure 7F). These in vitro results, together with our in
pitulated in vitro. In vivo studies with activated PPAR vivo gene expression data, clearly demonstrate that
described here and adipose-specific PPAR ablation PPAR controls fatty acids metabolism by promoting
(Barak et al., 2002) suggest that PPAR is not involved -oxidation and energy uncoupling in peripheral tissues.
in adipogenesis. In support of the in vivo data, we found Our results also indicate that, unlike PPAR, PPAR
no inhibitory or stimulatory effects of PPAR on 3T3- and PPAR have very limited thermogenic roles in both
L1 adipocyte differentiation (data not shown). We next adipose and skeletal muscle.
determined whether overexpression of PPAR pro- The thermogenic function of PPAR described here
motes triglyceride consumption (Figures 7A and 7B). is remarkably similar to that of the transcriptional coacti-
Preadipocytes were allowed to reach a fully differenti- vator PGC-1, raising the possibility that PGC-1 acts
ated state with triglyceride accumulation and then in- through PPAR to promote thermogenesis. Indeed, in
fected with virus expressing PPAR or VP16-PPAR. 293 cells overexpressing PPAR and PGC-1, coimmu-
We assayed the levels of glycerol released into culture noprecipitation studies reveal a strong physical interac-
medium as an indicator of triglyceride metabolism. As tion between these two proteins (Figure 7G). This inter-
shown in Figure 7A for a 6 hr time point, overexpression action is enhanced by addition of GW501516 and
of PPAR leads to a 2-fold increase in glycerol release. critically depends on the LXXLL receptor interaction mo-
This increase is due to activation of PPAR by intracellu- tif located between amino acids 142–146 of PGC-1. A
lar fatty acids as endogenous ligands. Indeed, addition residual interaction exists in the LXXLL motif mutant
of the more potent PPAR selective agonist GW501516 (LxxAA), but, unexpectedly, disappears in the presence
further enhances the production of glycerol. Overex- of the PPAR agonist. In agreement with the interaction
pression of VP16-PPAR results in a 3-fold production. data, PGC-1, even in the absence of agonist, is a pow-
A similar fold induction is observed over a 46 hr time erful coactivator for PPAR in transient transfection re-
point, with correspondingly increased glycerol levels in porter assays of C2C12 muscle cells (Figure 7H). In con-
the medium (data not shown). We also measured total trast, the coactivator p300, the p160 family member
ACTR, or the LXXLL mutant of PGC-1 is inactive. Fi-intracellular triglyceride levels following virus infection.
PPAR in Lipid Metabolism and Obesity Resistance
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Figure 7. PPAR Promotes Fatty Acid -Oxidation and Utilization in Adipocytes and Myotubes, and Associates with the Thermogenic Cofactor
PGC-1
(A) Triglyceride breakdown. Fully differentiated 3T3-L1 cells were infected with adenovirus expressing GFP, VP16, PPAR (), or VP16-PPAR
(VP16-) overnight. Cells were then washed and serum-starved overnight with or without GW501516 (GW) ligand (0.1 M). The next day cells
were washed again and incubated with the serum-free medium for 6 hr. Glycerol released into the medium was assayed.
(B) Four days postvirus infection, adipocytes were lysed and levels of total triglycerides assayed.
(C and D) -oxidation in adipocytes. (C) 3T3-L1 preadipocytes two day postconfluence were incubated with ligands GW501516 (0.1 M),
WY14643 (WY) (15 M), or BRL49653 (BRL) (1 M) overnight, or (D) 3T3-L1 preadipocytes were infected with indicated adenovirus with or
without indicated ligands (0.1 M for GW501516, 1 M for BRL) overnight. Next day cells were changed to serum-free medium containing
3H-palmitic acids. 3H2O production was assayed 7 hr after incubation.
(E) -oxidation in myotubes. Differentiated C2C12 muscle cells were treated as above. 3H2O production was assayed 4 hr after incubation.
Data were from quadruplicates.
(F) Target gene expression in myotubes. Myotubes were treated with vehicle, GW501516 (0.1 M), WY14643 (15 M), or BRL49653 (1 M)
for 24 hr. Total RNA was then isolated and analyzed (10 g/lane) by Northern blot with indicated probes. ACC2, acetyl CoA carboxylase 2;
FATP4, fatty acid transporter protein 4.
(G) Interaction of PPAR and PGC-1 in 293 cells. Cells were transfected with HA-PPAR and Flag-PGC-1 or Flag-PGC-1 142LXXLL146 motif
mutant (LXXAA), then treated with vehicle or GW501516 (0.1 M) as indicted. HA-PPAR was immunoprecipitated with anti-HA affinity beads
and precipitated proteins were probed with anti-flag antibodies.
(H) PGC-1 coactivates PPAR in C2C12 muscle cells. Luciferase activity was normalized with -gal activity. Shown are folds of induction
calculated based on the activity from transfections without coactivator and GW501516 (first bar  70 arbitrary units).
(I) Interaction of PPAR and PGC-1 in gastrocnemius muscle. The nuclear extracts were incubated with protein A beads alone (lane 1), beads
with PPAR antibodies in the absence (lane 2) or presence of GW501516 (0.1 M; lane 3). Precipitated proteins were probed with PGC-1
antibodies. The PGC-1 bands (arrow) were verified by two different PGC-1 antibodies.
nally, we determined whether PPAR and PGC-1 asso- scoring their clinical significance in metabolic disorders.
In contrast, little is known for PPAR in lipid metabolism.ciate in thermogenic tissues. We isolated nuclear ex-
tracts from gastrocnemius muscle of mouse. Both Here, we demonstrate both in vivo and in vitro that
PPAR plays a critical role in a coordinated metabolicPPAR and PGC-1 protein are present in the prepara-
tions. PPAR antibodies coimmunoprecipitate PGC-1 program by upregulating fatty acid oxidation and energy
expenditure.from the nuclear extracts (Figure 7I), suggesting an
association between PPARand PGC-1 in vivo at phys-
iological conditions. These results provide additional PPAR and Adipocyte Differentiation
support for the hypothesis that PGC-1 regulates ther- Expression of activated PPAR in adipose tissue unex-
mogenesis at least in part through activation of PPAR. pectedly leads to a lean phenotype in the transgenic
mice; yet these mice eat normally. This indicates that
the reduction of adipose mass may occur by one ofDiscussion
two different mechanisms: disruption of adipogenesis
or elevated energy dissipation. Defects in adipogenesisRecent studies have uncovered distinct and tissue-
restricted functions for PPAR and PPAR, each under- typically result in irregular metabolic features such as
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fatty liver, hypertriglyceridemia, and insulin resistance two proteins associate in thermogenic tissues in vivo.
Taken together, we suggest that many of the thermo-(Moitra et al., 1998; Shimomura et al., 1998; Barak et al.,
1999). However, no components of this triad are found genic effects of PGC-1 may be mediated through
PPAR.in the VP16-PPAR transgenic mice. Finally, neither acti-
vation of PPAR in preadipocytes in vitro nor targeted
knockout of PPAR in adipose tissue in vivo shows any PPAR Members in Lipid Metabolism:
effect on adipose differentiation. Complementary or Opposing Roles
Our work reveals interesting parallels between PPAR
and PPAR. For example, the -oxidation genes in-PPAR in Fatty Acid Oxidation and Energy
duced by PPAR in adipose tissue largely overlap withUncoupling
PPAR target genes in the liver. Similarly, as seen inSeveral previous studies indicate that PPAR may be
VP16-PPAR transgenic mice, pharmacological activa-involved in aspects of fatty acid metabolism, but its
tion of PPAR by its agonists also lowers serum triglyc-exact role and to what extent it can affect whole body
eride levels. In addition, it has been shown that certainphysiology are not known (Leibowitz et al., 2000; Peters
long chain fatty acids, especially polyunsaturated fattyet al., 2000; Oliver et al., 2001; Vosper et al., 2001; Barak
acids, are potent activators for both PPAR and PPAR,et al., 2002). We show here that activation of PPAR in
but are poor ligands for PPAR (Forman et al., 1997).vivo leads to systematic metabolic changes and this is
These parallels in PPAR and PPAR responsivenessachieved by elevating fatty acid catabolism and energy
are contrasted by their distinctive patterns of expres-expenditure. Increased catabolism lowers circulating
sion. In particular, PPAR is widely expressed whilelevels of triglycerides and free fatty acids and prevents
PPAR shows a prominent liver profile, leading to theadipocyte hypertrophy and lipid accumulation. More-
idea that PPAR and PPARmay act in a tissue-comple-over, under caloric overload, activation of PPAR not
mentary manner. While a major role for PPAR in liveronly produces a pronounced improvement in the lipid
is to produce ketone bodies as fuel through -oxidationprofile, but also protects against high-fat diet- or hyper-
for peripheral tissue during fasting, PPARmay regulatephagia-induced obesity and essentially eliminates the
combustion of locally available fatty acids and maintaindevelopment of fatty liver. Consistent with these obser-
energy balance.vations, key genes required for fatty acid -oxidation
In both adipose tissue and cultured adipocytes,and energy uncoupling are significantly upregulated. In
PPAR and PPAR appear to serve two opposing func-vitro, we show that activation of PPAR stimulates fatty
tions in fatty acid metabolism, namely catabolism versusacid -oxidation and triglyceride utilization in adipo-
lipogenesis and storage. In contrast to the role of PPARcytes and myotubes in vitro. In parallel, we observed
described here, activation of PPAR promotes free fattythat PPAR-deficient mice challenged with high-fat diet
acids influx into adipose tissue, thereby leading to in-show reduced energy uncoupling and are prone to dra-
creased adiposity and weight gain (Yamauchi et al.,matic weight gain. Thus, we identify PPAR as a key
2001b). Interestingly, recent studies suggest the exis-metabolic regulator of fat burning.
tence of a similar but reversed analogy for cholesterolDiet-induced adaptive thermogenesis is known to oc-
metabolism in macrophages. While PPAR promotescur in both brown fat and muscle in response to energy
cholesterol accumulation in human macrophages (Vos-overload. Metabolic activation of fat and muscle is ex-
per et al., 2001), PPAR increases cholesterol efflux totremely important in protection against the development
protect against atherosclerosis (Li et al., 2000; Chawlaof obesity. We show here that, as a dietary lipid sensor,
et al., 2001a; Akiyama et al., 2002). These different bio-PPAR links dietary status to thermogenesis. PPAR
logical effects are exerted largely by the ability of thesepowerfully stimulates and coordinates at least two im-
receptors to sense different lipids along with their activa-portant aspects of this program: fuel oxidation and un-
tion of distinct sets of target genes. We find that thecoupling. This unique function enables cells to maintain
PPAR target genes in adipose tissue that are directlya normal cellular ATP/ADP ratio to meet the energy de-
implicated in lipogenic and storage pathways are simplymands while dissipating extra energy as heat. Recent
not induced by activation of PPAR. How receptors withwork by Spiegelman’s group and others clearly estab-
similar DNA binding domains achieve these opposinglished that the nuclear cofactor PGC-1 is a central
effects is not understood.component of adaptive thermogenesis (Puigserver et
al., 1998; Wu et al., 1999; Picard et al., 2002); however,
the major target transcriptional pathway through which PPAR in Anti-Obesity Therapies
Obesity is a devastating medical and social problemit mediates this effect is not known. Our data suggest
that PPARmay be the unidentified factor. The fact that with increasing prevalence of potentially epidemic pro-
portions. Manipulation of adaptive thermogenesis hasthese two proteins both activate thermogenesis in the
same tissues by regulating common target genes lead long been pursued to treat obesity (Spiegelman and
Flier, 2001). For example, thyroid hormones stimulateus to speculate that PPAR may employ PGC-1 as its
predominant coactivator in this pathway. This idea is thermogenesis by an uncertain mechanism and can pro-
mote weight loss, but they also produce side effectsfurther enforced by their induction of UCP genes in a
similar cell type-selective pattern. In white fat, both such as loss of lean body mass and cardiac toxicity.
The identification of players in this pathway could createPGC-1 and PPAR induce UCP1 but not UCP2 or
UCP3, whereas in muscle both induce UCP2 and UCP3, pharmacologic opportunities. Even though PGC-1 and
the uncoupling proteins are potential therapeutic tar-but not UCP1. We find that PGC-1 is a potent coactiva-
tor for PPAR in muscle cells and, importantly, these gets, PPAR as a nuclear receptor, represents a bona
PPAR in Lipid Metabolism and Obesity Resistance
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Reporter Assaysfide target. In particular, its ability to induce adaptive
C2C12 myoblasts (80% confluence) in 24-well plates were trans-thermogenesis and protection against both dietary and
fected using lipofectamine 2000 (Invitrogen) with 0.2 g PPRE-lucif-genetic obesity suggests that PPAR agonists may be
erase reporter, 0.2 g -gal, 0.02 g PPAR, and 0.04 g indicated
promising drug candidates for anti-obesity therapies. coactivators. Cells were treated with GW501516 as described
above. Luciferase activity was normalized with -gal activity. Fold
Experimental Procedures of induction was calculated based on the activity from transfections
without coactivator and GW501516.
Animals
To generate VP16-PPAR transgenic mice, the transactivation do- Assays for Fatty Acid Utilization in Cultured Cells
main (78 amino acid residues, corresponding to 413–490 residues) PPAR and PPAR adenovirus were kindly provided by Dr. W. He.
of VP16 was fused in frame with the N terminus of mouse PPAR. The VP16-PPAR adenoviruses were generated using the AdEasy sys-
VP16-PPAR cDNA was placed downstream of the 5.4 kb promoter/ tem as previously described (He et al., 1998). The virus were purified
enhancer of the mouse aP2 gene (Ross et al., 1990) and upstream and concentrated by cesium chloride ultracentrifugation. A multi-
of the SV40 intron/poly (A) sequence. The transgene was purified plicity of infection of 30 plaque-forming units/cell was used.
and injected into C57BL/6J 	 CBA F1 zygotes. Transgene positive 3T3-L1 preadipocytes placed in 12-well plates were cultured in
mice were screened by Southern blot and PCR. Transgenic founder Dulbecco’s modified Eagle’s medium (DMEM) containing 10% bo-
lines were backcrossed with C57BL/6J. Wild-type littermates were vine calf serum and differentiated using standard protocols with 0.5
used as controls throughout the study. As an additional control, we mM 3-isobutyl-1-methylxanthine, 0.25 M dexamethasone, and 5
also generated aP2-VP16 transgenic mice, which behave identically g/ml insulin as inducers (Hamm et al., 2001). Differentiation of
to wild-type animals. Null and adipose-specific PPAR knockout C2C12 cells into myotubes was performed with standard protocol.
mice have been described previously (Barak et al., 2002). Mice were For triglyceride breakdown assay, fully differentiated 3T3-L1 adi-
fed a standard chow with 4% (w/w) fat content (Harlan Teklad). For pocytes were infected with virus. The next day cells were washed
high-fat feeding, a diet containing 35% (w/w) fat content (product and serum-deprived with DMEM medium containing 2% (w/v) fatty
F3282, Bioserv) was used. acid-free BSA (Sigma) with or without ligands overnight. Cells were
washed again and incubated in the same serum-free medium. Glyc-
Histology erol levels in the incubation medium were determined using a colori-
Tissues were fixed in 10% formalin, dehydrated, embedded in paraf- metric assay (GPO-Trinder, Sigma). Cells were lysed and triglyceride
fin, and sectioned for haematoxylin and eosin (H&E) staining. Images (Sigma) and protein content (Bio-Rad) were determined.
were captured using Axio Vision 2.05 imaging system (Zeiss) and For -oxidation assay, 3T3-L1 preadipocytes two days postcon-
processed in Adobe Photoshop. fluence or C2C12 myotubes were either treated with ligands, or
infected with virus (with or without ligands), for 30 hr. Cells were
washed and incubated in low glucose DMEM medium (CatalogueLigand Treatment of Leprdb/db Mice
#11885, GIBCO) containing 2% (w/v) fatty acid-free BSA, 0.30 mMWe synthesized the GW501516 compound. Leprdb/db mice were ob-
L-carnitine, and 3H-palmitic acid (3 Ci/well). Excess 3H-palmitictained from Jackson laboratory. GW501516 was freshly prepared
acid in the medium was removed by trichloroacetic acid precipita-in 0.5% carboxymethyl cellulose at a concentration of 4 mg/ml. Age-
tion twice. The supernatant was extracted with chloroform:methanoland weight-matched mice were treated by oral gavage either with
(2:1) twice and then counted for 3H2O production.vehicle or 10 mg/kg per day of GW501516 for 7 days. Brown fat
and liver were obtained for histology analysis.
Statistical Analysis
Number of mice for each group used in experiments is indicated inAnalytical Procedures
the figure legends. Values were presented as mean  SEM. A two-Mice were fasted for 6 hr before blood was drawn. Enzymatic kits
tailed student’s t test was used to calculate P values.were used for measuring serum nonesterified fatty acids (Wako),
total triglycerides, and total cholesterol (Sigma).
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